Guerbet's Stock Soars 7%, Up +26% Over the Week
The stock of the medical imaging contrast agent specialist soared this Monday, April 27, 2026, showing an increase of over 7% in mid-afternoon. This spectacular rebound brings the weekly performance to more than 26%, after several months of significant decline. The stock is now trading well above its short-term moving averages, in a nearly stable Parisian market context.
Weekly Rally Propels Stock into Technical Overbought Zone
Guerbet's stock is trading around €12.44 during the session, up 7.06% from last Friday's close of €11.62. Over seven days, the stock has accumulated a gain of 26.29%, a movement all the more remarkable as the stock still shows a decline of 34.46% over the past year. From a technical analysis perspective, the price has significantly crossed the upper boundary of the Bollinger Bands, set at €10.90, which constitutes a classic signal of potential overbuying. The stock is also well above its 50-day moving average (€10.89), which it crossed upwards last week. The RSI, at 67, is approaching the overheating zone without yet reaching it, reflecting the intensity of the recent acceleration. This movement occurs in a sluggish Parisian market: the CAC 40 is barely up 0.01% in session, while the SBF 120 is up 0.03%.
Busy Financial Calendar Ahead for the Group
While the stock is recovering some of the lost ground — it is still down more than 10% over three months — upcoming deadlines could provide crucial insights. Guerbet's annual general meeting is scheduled for Friday, May 22, 2026, an event likely to provide details on the group's strategy and distribution policy. Investors are then awaiting the publication of the second quarter's revenue, scheduled for Thursday, July 23, followed by the first half of 2026 results on Tuesday, September 15. It should be noted that the current price remains significantly below the 200-day moving average, which is at €15.26, a gap that illustrates the magnitude of the correction suffered over the past year. The former resistance of €11.62, corresponding to the last closing price, could now act as a support in case of consolidation. The very low beta of the stock (0.16) also indicates a historically limited sensitivity to general market movements, making the current rebound all the more specific to the stock.
